Company Overview
Snapshot
Founded in January 2006 by Gila Maor, CartiCure operates with 1–10 employees. The company is dedicated to developing cartilage repair products and has successfully completed pre-clinical studies in large and small animals, securing a granted US patent for its technology.
Business overview
CartiCure is an early-stage company focused on developing innovative cartilage repair products within the Health Tech & Life Sciences sector. Its core technology generates original hyaline cartilage-producing cells for transplantation into damaged joints, aiming to efficiently replenish lesions in articular cartilage. The company's initial product, Cartimove, targets knee cartilage damage from trauma injuries, with a next-generation product aimed at the osteoarthritis market. CartiCure operates in the medical devices and medical treatment & therapeutics categories, serving the healthcare and medical devices industries, particularly in the United States.
Log in to access full profile ›Company Intelligence Q&A
- When was CartiCure founded?
- CartiCure was founded in January 2006.
- Who is the founder of CartiCure?
- Gila Maor is the founder and CTO of CartiCure.
- What is CartiCure's primary focus?
- CartiCure is dedicated to the development of cartilage repair products, utilizing a technological platform that generates original hyaline cartilage-producing cells.
- What is CartiCure's first product?
- CartiCure's first product, Cartimove, is designed for the treatment of knee cartilage damage resulting from trauma injuries.
- What is the status of CartiCure's pre-clinical studies?
- CartiCure has successfully completed pre-clinical studies performed in large and small animals.